NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 21.0% from a year ago
Cash & equivalents stood at $6.71M at the end of Q1 FY2026, up 21.0% from a year earlier and down 13.9% from the prior quarter. Over 3 fiscal years it compounded at -27.0% a year.
Context
- Cash & equivalents amounted to 56.4% of total assets at the end of Q1 FY2026, down 16.7 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +21.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 7.8M USD
- Year-over-year change
- +440.3%
- 4-year CAGR
- -27.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.8M | +440.3% |
| FY2024 | 2024-12-31 | 1.44M | -68.6% |
| FY2023 | 2023-12-31 | 4.6M | -77.1% |
| FY2022 | 2022-12-31 | 20.05M | -27.4% |
| FY2021 | 2021-12-31 | 27.61M | — |
Cash & Equivalents vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 cash & equivalents of $6.71M is the 8th highest of the 9 companies compared; the peer median is $36.52M.
- Its year-over-year change of +21.0% is the 6th highest of 9, against a peer median of +23.4%.
- Cash & equivalents amounts to 56.4% of total assets for NRXP, versus a peer median of 61.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $90.85M | +134.3% | -23.5% | 69.1% | |
| Mar 2026 | $61.32M | +322.9% | -20.0% | 97.2% | |
| Mar 2026 | $54.08M | +111.1% | +25.9% | 96.3% | |
| Mar 2026 | $51.05M | -1.6% | -9.8% | 15.6% | |
| Jun 2026 | $21.99M | -71.7% | -23.5% | 91.0% | |
| Mar 2026 | $16.38M | +24.7% | -19.3% | 53.0% | |
| Mar 2026 | $7.75M | +2.5% | -22.5% | 35.4% | |
| Mar 2026 | $6.71M | +21.0% | -27.0% | 56.4% | |
| Mar 2026 | $5.21M | +22.1% | +14.4% | 26.3% | |
| Peer median (excluding NRXP) | $36.52M | +23.4% | -19.6% | 61.1% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.